Results 151 to 160 of about 16,238 (237)

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL‐1β Kinetics [PDF]

, 2012
Sihem Ait‐Oudhia, Philip J. Lowe, DE Mager   +2 more
openalex   +1 more source

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up [PDF]

, 2011
R Caorsi, L Lepore, F Zulian, M Alessio, A Stabile, M Finetti, A Martini, M Gattorno   +7 more
core   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. [PDF]

Arthritis Rheumatol
Eviatar T, Capelusnik D, Campochiaro C, Lacombe V, Jachiet V, Zisapel M, Sagy I, Tayer-Shifman OE, Ozeri D, Kivity S, Tomelleri A, Terrier B, Peleg H, Comont T, Sacre K, Woaye-Hune P, Arnaud L, Lazaro E, Grobost V, Lifermann F, Samson M, Ardois S, Garnier A, Maria A, Cantagrel A, Meyer A, Bouaziz JD, Heiblig M, Dagna L, Diral E, Kosmider O, Elkayam O, Hadjadj J, Georgin-Lavialle S, Fain O, Mekinian A.   +35 more
europepmc   +1 more source

The promise of IL-1β modulation in NSCLC clinical context. [PDF]

Front Immunol
Ghiringhelli F, Rébé C.
europepmc   +1 more source

Table 1_Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.docx

Hao Liu (12832), Wei Yan (4327), Jinsong Li (255117), Dezhi Yan (20445454), Di Luo (1617946)   +4 more
openalex   +1 more source

Buzzing Away Pain: Efficacy of Buzzy® in Reducing Pain During Canakinumab Treatment for Familial Mediterranean Fever [PDF]

Nebahat Zeynep Özaslan, Betül Öksel, Nihal Şahin, Hafize Emine Sönmez   +3 more
openalex   +1 more source

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen [PDF]

, 2012
Paul M. Ridker, Campbell P. Howard, Verena Walter, Brendan Everett, Peter Libby, Johannes Hensen, Tom Thurén   +6 more
openalex   +1 more source

Genotype-phenotype correlations in pediatric CAPS with predominantly low-penetrance NLRP3 variants among Turkish patients in Germany and Turkey: beyond borders. [PDF]

Pediatr Rheumatol Online J
Bayindir Y, Satirer Ö, Cam V, Turkmen S, Sozeri B, Kuemmerle-Deschner JB, Ozen S.   +6 more
europepmc   +1 more source

Three-year follow-up of canakinumab dose extension in children with colchicine-resistant familial Mediterranean fever: PeRA-RG Experience. [PDF]

Rheumatology (Oxford)
Kavrul Kayaalp G, Çağlayan Ş, Ulu K, Türkmen Ş, Demirkan FG, Guliyeva V, Otar Yener G, Öztürk K, Demir F, Özdel S, Çakan M, Sönmez HE, Sözeri B, Aktay Ayaz N, PeRA Research Group .   +14 more
europepmc   +1 more source

The journey of canakinumab; on- and off-label indications

, 2019
Daniela Marotto, Alberto Batticciotto, Angela Ceribelli, Piercarlo Sarzi‐Puttini   +3 more
openalex   +2 more sources